The current review provides an overview of the thrombotic risk observed in patients with MG who do not otherwise require treatment. We discuss clinical and biomarker studies that highlight the heterogenous hemostatic profile observed in these patients and how knowledge has evolved over the past 20 years. Biomarker studies suggest shared biologic features between multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS), which involves both hypercoagulability and platelet activation. Hemostatic abnormalities identified in MGUS patients cannot be translated into clinical practice as they lack correlation to clinical events. The prothrombotic phenotype of MGUS patients has not been ascertained yet, but novel data on coagulation markers are promising. We also review rare conditions associated with the thrombogenic properties of the monoclonal protein that predispose to arterial, venous or microthrombotic events and demonstrate that the M-protein can be linked to clinically significant thrombotic events. Cryoglobulinemia, cryofibrinogenemia, cryo-crystaloglobulinemia and MG-related antiphospholipid syndrome are reviewed. We propose the new umbrella term “monoclonal gammopathy of thrombotic significance” (MGTS) to refer to significant, recurrent thrombotic events in patients with MGUS that provide a rationale for targeting the underlying plasma cell clone. Identifying MGUS patients at high risk for thrombotic events is currently a challenge.
1 December 2019 in The American Journal of Medicine
Bottom‐up proteomics relies on efficient and repeatable sample preparation for accurate protein identification and precise quantification. This study evaluates the performance of adapted SPEED (Sample Preparation by Easy Extraction and Digestion) protocol, a simplified, detergent‐free approach tailored for various biological matrices, including lysis‐resistant samples. Protein extraction and denaturation steps were refined for 8 biological matrices enabling standardized, cheap, and scalable proteomics analysis on 96‐well plates. For tissue samples requiring downstream applications like Western blotting, we used a low‐detergent RIPA buffer. Notably, the protocols demonstrate remarkable down‐scalability, enabling robust proteomics measurements from as few as 3000 cells per sample for preparation and even down to 300 cells per LC‐MS/MS analysis. Key advancements include a 30‐min nanoLC‐MS/MS run, achieving a 15–20 samples‐per‐day throughput, and leveraging the power of diaPASEF using thoroughly optimized DIA‐windows to enhance proteome coverage. These adaptations streamline workflows, enabling proteomics analyses in matrices with challenging physical and biochemical properties. This study underscores the importance of early‐stage optimization and feasibility testing in proteomics pipelines to inform study design and sample selection. By showcasing robust, scalable adaptations of the SPEED protocol, we provide a foundation for reproducible, high‐throughput proteomic studies across diverse biological contexts.
• Crystalglobulinemia is associated with a procoagulant platelet phenotype and high shear stress-like endothelial alterations. • Markers of platelet and endothelial function reflect monoclonal protein burden.
Randall-type monoclonal immunoglobulin deposition disease (MIDD) is an unusual complication of plasma cell disorders with Congo red negative non-organized deposits of monoclonal light chain (LCDD),...